Whereas 30 years ago just one in five prescribed preparations was a generic (21.9 percent), the situation is now almost reversed: 78.7 percent of prescriptions in 2019 were generics - this is shown by the figures of the industry association Pro Generika. However, they only account for just under nine percent of the drug expenditure of the statutory health insurance (SHI).
The same quality requirements apply to generics as to initial supplier products, and they are just as effective. In the meantime, so-called copycat drugs have become the most important weapon in the fight against the major common ailments. They make up the majority of the drugs that doctors prescribe most frequently. Of the ten most frequently prescribed active ingredients, nine are supplied almost entirely by generic companies. This reinforces our philosophy: we produce medicines that are of high quality and at the same time cost-effective for patients. These are generics of important original products, supplemented by in-house developments and over-the-counter OTC products, most of which are manufactured at our own production sites in Germany and Spain. In this way, we aim to ensure that as many people as possible can benefit from the high standard of modern pharmaceuticals - also and especially in times of the global pandemic.